Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bridging Biosciences LLC is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is handled by 1 distinct examiner and 1 distinct art unit, indicating that the company's current intellectual property efforts are highly centralized. In the biotech sector, such a focused prosecution profile often points to a specific biological innovation being examined by a single specialized group.
VAN BUREN, LAUREN K is the busiest examiner for the company, overseeing 1 pending office action. Because the portfolio contains only 1 pending action in total, this examiner has exclusive oversight of the company's current patent pipeline. The 1 distinct art unit involved will dictate the procedural rules and timelines for this case. Consequently, the company's strategy must be tailored to the specific expectations of VAN BUREN, LAUREN K, as there are no other active matters to balance the prosecution risk across different examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAN BUREN, LAUREN K | 1 | 40.0% | +58.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18111439 | INTRAVENOUS ADMINISTRATION OF SUPRAPHYSIOLOGIC PLATELET RICH PLASMA FOR NEUROLOGICAL DISORDERS | VAN BUREN, LAUREN K | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18111439 | INTRAVENOUS ADMINISTRATION OF SUPRAPHYSIOLOGIC PLATELET RICH PLASMA FOR NEUROLOGICAL DISORDERS | VAN BUREN, LAUREN K | 1638 | §112 | Final Rejection | — | Pending | Feb 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBridging Biosciences LLC has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Lauren K Van Buren has the most, with 1 of Bridging Biosciences LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.